Roundtable – Breaking Down Barriers in the Traditional Dogma of Drug Development for GBM to Overcome Delays in Bringing Combination Therapies to Patients
- How can the GBM field move beyond traditional IP models to foster collaboration for combination therapies?
- How can the GBM community standardize preclinical models, data, and trial designs to prevent the wasteful duplication of work?
- What changes are needed in trial design and regulatory pathways to overcome the delays in bringing combination therapies to market?